Bank of Montreal Can boosted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 28.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 65,210 shares of the biopharmaceutical company’s stock after buying an additional 14,364 shares during the quarter. Bank of Montreal Can owned 0.06% of Alnylam Pharmaceuticals worth $5,706,000 as of its most recent SEC filing.
A number of other hedge funds also recently made changes to their positions in the business. Rockefeller Capital Management L.P. boosted its stake in shares of Alnylam Pharmaceuticals by 8.2% in the second quarter. Rockefeller Capital Management L.P. now owns 268,111 shares of the biopharmaceutical company’s stock valued at $26,406,000 after purchasing an additional 20,357 shares during the period. Riverhead Capital Management LLC boosted its stake in shares of Alnylam Pharmaceuticals by 195.6% in the second quarter. Riverhead Capital Management LLC now owns 2,365 shares of the biopharmaceutical company’s stock valued at $233,000 after purchasing an additional 1,565 shares during the period. Advisors Asset Management Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 269.8% in the second quarter. Advisors Asset Management Inc. now owns 54,368 shares of the biopharmaceutical company’s stock valued at $1,674,000 after purchasing an additional 39,665 shares during the period. Amalgamated Bank boosted its stake in shares of Alnylam Pharmaceuticals by 11.3% in the second quarter. Amalgamated Bank now owns 20,420 shares of the biopharmaceutical company’s stock valued at $2,011,000 after purchasing an additional 2,080 shares during the period. Finally, NumerixS Investment Technologies Inc purchased a new position in shares of Alnylam Pharmaceuticals in the second quarter valued at approximately $398,000. 90.09% of the stock is owned by institutional investors.
ALNY stock opened at $80.43 on Thursday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 13.22 and a current ratio of 13.22. Alnylam Pharmaceuticals, Inc. has a twelve month low of $71.85 and a twelve month high of $153.99. The company has a market cap of $7.73 billion, a price-to-earnings ratio of -14.84 and a beta of 2.55.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported ($1.63) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.74) by $0.11. Alnylam Pharmaceuticals had a negative net margin of 533.52% and a negative return on equity of 38.09%. The company had revenue of $29.91 million for the quarter, compared to analysts’ expectations of $16.96 million. During the same quarter last year, the company earned ($1.07) earnings per share. The firm’s revenue for the quarter was up 87.8% on a year-over-year basis. As a group, analysts predict that Alnylam Pharmaceuticals, Inc. will post -7.28 earnings per share for the current year.
In other Alnylam Pharmaceuticals news, COO Yvonne Greenstreet sold 2,500 shares of the firm’s stock in a transaction that occurred on Thursday, August 30th. The shares were sold at an average price of $120.00, for a total transaction of $300,000.00. Following the sale, the chief operating officer now owns 1,916 shares of the company’s stock, valued at $229,920. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 3.70% of the stock is currently owned by company insiders.
ALNY has been the subject of several recent research reports. Jefferies Financial Group reissued a “buy” rating and issued a $149.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Monday, August 6th. JMP Securities set a $198.00 target price on shares of Alnylam Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, August 28th. Piper Jaffray Companies reaffirmed an “overweight” rating on shares of Alnylam Pharmaceuticals in a report on Monday, July 23rd. BMO Capital Markets reduced their target price on shares of Alnylam Pharmaceuticals from $125.00 to $124.00 and set an “outperform” rating on the stock in a report on Tuesday, October 16th. Finally, Morgan Stanley reduced their target price on shares of Alnylam Pharmaceuticals from $93.00 to $87.00 and set an “equal weight” rating on the stock in a report on Friday, September 28th. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating and fifteen have assigned a buy rating to the company’s stock. Alnylam Pharmaceuticals has an average rating of “Buy” and an average target price of $143.82.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia.
Recommended Story: Understanding the different types of bonds
Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.